- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.08. | Viking hits stormy seas as phase 2 oral obesity data sink stock | ||
| 19.08. | VantAI plays matchmaker for Halda's 'hold-and-kill' drugs in $1B deal | ||
| 19.08. | Opthea, still reeling from eye disease flops, ramps up cuts to 85% of staff and loses CEO | ||
| 19.08. | China's RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal | ||
| 19.08. | CSL to lay off up to 15% of workforce, cut R&D costs and spin out vaccine unit | ||
| 18.08. | Shankar Ramaswamy's gene therapy biotech raises $313M | ||
| 18.08. | Genentech scraps $2B deal with cell therapy biotech | ||
| 18.08. | Stealth Bio submits third FDA application for rare disease candidate | ||
| 18.08. | Neurizon becomes second biotech hit with FDA delay for ALS candidate | ||
| 18.08. | Boehringer pens $327M pact with Palatin to develop new therapies for diabetic retinopathy | ||
| 18.08. | Merck KGaA swoops into Skyhawk neurological disease pact worth up to $2B | ||
| 18.08. | Reunion's psychedelic prodrug reduces postpartum depression symptoms in phase 2 study | ||
| 18.08. | Pfizer's SCD drug fails phase 3 study in latest blow to Global Blood Therapeutics' legacy | ||
| 15.08. | FDA delays Omeros' 2nd attempt at transplant drug's approval by 3 months | ||
| 14.08. | Evotec's reorg claims 600 jobs, hundreds more than originally planned | ||
| 14.08. | Cancer biotech Prelude calls it curtains on lead SMARCA2 degrader | ||
| 14.08. | Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs | ||
| 14.08. | Schrödinger abandons CDC7 inhibitor after therapy is linked to 2 patient deaths | ||
| 14.08. | CytomX reports patient death from kidney injury in ADC trial | ||
| 13.08. | Vedanta's live bacteria cocktail fails to reduce ulcerative colitis severity in ph. 2 trial | ||
| 13.08. | VC firm Hatteras reels in $200M across 2 funds for early-stage life sciences investments | ||
| 13.08. | Response's ex-Sanofi asset hits midphase goal in post-GLP-1 patients | ||
| 13.08. | Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs | ||
| 13.08. | Generation jettisons 90% of employees due to lack of time, cash to develop autoimmune tech | ||
| 12.08. | NIH director says public distrust prompted federal mRNA vaccine development discontinuation |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .